AAAAAA

   
Results: 1-2 |
Results: 2
Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: A study of the European Organization for Researchand Treatment of Cancer Early Clinical Studies Group
Authors: Briasoulis, E Judson, I Pavlidis, N Beale, P Wanders, J Groot, Y Veerman, G Schuessler, M Niebch, G Siamopoulos, K Tzamakou, E Rammou, D Wolf, L Walker, R Hanauske, A
Citation: E. Briasoulis et al., Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: A study of the European Organization for Researchand Treatment of Cancer Early Clinical Studies Group, J CL ONCOL, 18(20), 2000, pp. 3535-3544
Weekly docetaxel in minimally pretreated cancer patients: A dose-escalation study focused on feasibility and cumulative toxicity of long-term administration
Authors: Briasoulis, E Karavasilis, V Anastasopoulos, D Tzamakou, E Fountzilas, G Rammou, D Kostadima, V Pavlidis, N
Citation: E. Briasoulis et al., Weekly docetaxel in minimally pretreated cancer patients: A dose-escalation study focused on feasibility and cumulative toxicity of long-term administration, ANN ONCOL, 10(6), 1999, pp. 701-706
Risultati: 1-2 |